Biopolymers as transdermal drug delivery systems in dermatology therapy

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 27, Issue 2, 2010, Pages 155-185

  Basavaraj, K H ^a   Navya, M A ^a   Johnsy, George ^b   Siddaramaiah, ^c   Rashmi, R ^a  

^a JSS MEDICAL COLLEGE   (India)

^b DEFENCE FOOD RESEARCH LABORATORY   (India)

^c SRI JAYACHAMARAJENDRA COLLEGE OF ENGINEERING   (India)

Author keywords

Biodegradable polymers; Biomaterials; Biopolymers; Drug delivery; Transdermal drug delivery

Indexed keywords

ALGINIC ACID; AMOXICILLIN; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOPOLYMER; CALCIUM CHANNEL BLOCKING AGENT; CHITOSAN; CLONIDINE; COLLAGEN; ESTRADIOL; FENTANYL; GLYCERYL TRINITRATE; HYALURONIC ACID; ISOSORBIDE DINITRATE; NANOPARTICLE; NICOTINE; NONSTEROID ANTIINFLAMMATORY AGENT; PECTIN; POLYLACTIC ACID; POLYSACCHARIDE; POLYURETHAN; PROTEIN; SCOPOLAMINE; SMALL INTERFERING RNA; TESTOSTERONE; UNINDEXED DRUG;

ALOPECIA; ALOPECIA AREATA; ATOPIC DERMATITIS; BIOCOMPATIBILITY; BIODEGRADATION; COLLAGEN SYNTHESIS; CONTROLLED DRUG RELEASE; DERMATOLOGY; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; DRUG PENETRATION; HERPES SIMPLEX; HUMAN; HYDROCOLLOID; HYDROGEL; INTERMETHOD COMPARISON; IONTOPHORESIS; METASTASIS; NONHUMAN; PATIENT COMPLIANCE; PROSTATE CANCER; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SKIN ABSORPTION;

EID: 77952915993     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevtherdrugcarriersyst.v27.i2.20     Document Type: Review

References (123)

1. Pillai O. Panchagnula R. Polymers in drug delivery. Curr Opin Chem Biol. 2001; 5: 447-451
2. Kotwal VB, Saifee M, Inamdar N. Bhise K. Biodegradable polymers: Which, when and why? Ind J Pharm Sci. 2007; 69: 616-625
3. Leong KW. Biodegradable polymers as drug delivery systems. In: Tarcha, PJ, editor. Polymers for controlled drug delivery. Boca Raton (FL): CRC Press; 1991. p. 128.
4. Valenta C, Auner BG. The use of polymers for dermal and transdermal delivery. Eur J Pharm Biopharm. 2004; 58: 279-289
5. Cosco D, Celia C. Cilurzo F, Trapasso E. Paolino D. Colloidal carriers for the enhanced delivery through the skin. Expert Opin Drug Dcliv. 2008; 5: 737-755
6. Barrett DA, Rutter N. Transdermal delivery and the premature neonate. Crit Rev Ther Drug Carrier Syst. 1994; 11: 1-30.
7. Wokovich AM, Prodduturi S. Doub WH, Hussain AS, Buhse LF. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute. Eur J Pharm Biopharm. 2006; 64: 1-8.
8. Bala I, Hariharan S, Kumar MN. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst. 2004; 21: 387-422.
9. Guy RH. Current status and future prospects of transdermal drug delivery. Pharm Res. 1996; 13: 1765-1769
10. Brown L, Langer R. Transdermal delivery of drugs. Annu Rev Med. 1988; 39: 221-229
11. Kaestli LZ, Wasilewski-Rasca AF, Bonnabry P, Vogt-Ferrier N. Use of transdermal drug formulations in the elderly. Drugs Aging. 2008; 25: 269-280
12. Cascone MG, Sim B, Downes S. Blends of synthetic and natural polymers as drug delivery systems for growth hormone. Biomaterials. 1995; 16: 569-574
13. Murphy M, Carmichael AJ. Transdermal drug delivery systems and skin sensitivity reactions. Incidence and management. Am J Clin Dermatol. 2000; 1: 361-368
14. Liu Z, Jiao Y, Wang Y, Zhou C, Zhang Z. Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliv Rev. 2008; 60: 1650-1662
15. Coviello T, Matricardi P, Marianecci C, Alhaique F. Polysaccharide hydrogels for modified release formulations. J Control Release. 2007; 119: 5-24.
16. Rouget C. Des substances amylace'es dans le tissu des animeaux, spe'cialement les articule's (chitine). Comptes Rendus. 1859; 48: 792-795
17. Hoppe-Seyler F. Ueber Chitosan und Zellulose. Ber Deut Chem Gesell. 1894; 27: 3329-3331
18. Paul W, Garside CP. Chitosan, a drug carrier for the 21st century: a review. STP Pharma Sci. 2000; 10: 5-22.
19. Schipper NG, Vårum K1VI. Artursson P. Chitosans as absorption enhancers for poorly absorbable drugs. 1: Influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells. Pharm Res. 1996; 13: 1686-1692
20. Prabaharan M. Chitosan derivatives as promising materials for controlled drug delivery. J Biomater Appl. 2008; 23: 5-36.
21. Brown MB. Martin GP. Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems: Current and future prospects. Drug Dcliv. 2006; 13: 175-187
22. Berger J, Reist M, Mayer JM, Felt 0, Gurny R. Structure and interactions in chitosan hydrogels formed by complexation or aggregation for biomedical applications. Eur J Pharm Biopharm. 2004; 57: 35-52.
23. Berger J, Reist M, Mayer JM, Felt 0, Peppas NA, Gurny R. Structure and interactions in covalently and ionically cross linked chitosan hydrogels for biomedical applications. Eur J Pharm Biopharm. 2004; 57: 19-34.
24. Silva CL, Pereirab JC, Ramalhoc A, Pais AACC, Sousa JJS. Films based on chitosan polyelectrolyte complexes for skin drug delivery: development and characterization. J Memb Sci. 2008; 320: 268-279
25. Dc la Torre PM, Enobakhare Y, Torrado G, Torrado S. Release of amoxicillin from polyionic complexes of chitosan and poly (acrylic acid). Study of polymer/ polymer and polymer/drug interactions within the network structure. Biomaterials. 2003; 24: 1499-1506
26. Rossi 5, Sandri G, Ferrari F, Bonferoni MC, Caramella C. Buccal delivery of acyclovir from films based on chitosan and polyacrylic acid. Pharm Dcv Technol. 2003; 8: 199-208.
27. Shu XZ, Zhu KJ, Song W. Novel pH-sensitive citrate cross-linked chitosan film for drug controlled release. mt J Pharm. 2001; 212: 19-28.
28. Kofuji K, Ito T, Murata Y, Kawashima S. Effect of chondroitin sulfate on the biodegradation and drug release of chitosan gel beads in subcutaneous air pouches of mice. Biol Pharm Bull. 2002; 25: 268-271
29. Chen WB, Wang LF, Chen JS, Fan SY. Characterization of polyelectrolyte complexes between chondroitin sulfate and chitosan in the solid state. J Biomed Mater Res A. 2005; 75: 128-137
30. Ahn JS, Choi HK, Chun MK, Ryu JM, Jung JH, Kim YU, Cho CS. Release of triamcinolone acetonide from mucoadhesive polymer composed of chitosan and poly (acrylic acid) in vitro. Biomaterials. 2002; 23: 1411-1416
31. Lin HR, Yu SP, Kuo CJ, Kao HJ, Lo YL, Lin YJ. Pilocarpine-loaded chitosanPAA nanosuspension for ophthalmic delivery. J Biomater Sci Polym Ed. 2007; 18: 205-221
32. Morganti P, Muzzarelli RAA, Muzzarelli C. Multifunctional use of innovative chitin derivatives for skin care. J Appl Cosmet. 2006; 24: 105-114
33. Fischer TK, Thatte HS, Nichols TC, Bender-Neal DE, Bellinger DA, Vournakis JN. Synergistic platelet integrin signaling and factor XII activation in poly-N-acetyl glucosamine fiber-mediated hemostasis. Biomaterials. 2005; 26: 5433-5443
34. Kössi J, Vähä-Kreula M, Peltonen 5, Risteli J, Laato M. Effect of sucrose on collagen metabolism in keloid, hypertrophic scar, and granulation tissue fibroblast cultures. World J Surg. 2001; 25: 142-146
35. Price RD, Myers 5, Leigh IM, Navsaria HA. The role of hyaluronic acid in wound healing-assessment of clinical evidence. Am J Clin Dermatol. 2005; 6: 393-402.
36. Ng KW, Tham W, Lim TC, Hutmacher DW. Assimilating cell sheets and hybrid scaffolds for dermal tissue engineering. J Biomed Mater Res A. 2005; 75A: 425-438
37. Tan SW, Johns MR, Greenfield PF. Hyaluronic acid--a versatile biopolymer. Aust J Biotechnol. 1990; 4: 38-43.
38. Liao YH, Jones SA, Forbes B, Martin GP, Brown MB. Hyaluronan: pharmaceutical characterization and drug delivery. Drug Dcliv. 2005; 12: 327-342
39. Brown MB, Jones SA. Hyaluronic acid: a unique vehicle for the localized delivery of drugs to the skin. J Eur Acad Dermatol Venereol. 2005; 19: 308-318
40. Shu XZ, Liu YC, Luo Y, Roberts MC, Prestwich GD. Disulfide cross-linked hyaluronan hydrogels. Biomacromolecules. 2002; 3: 1304-1311
41. Vercruysse KP, Marecak DM, Marecek JF, Prestwich GD. Synthesis and in vitro degradation of new polyvalent hydrazide cross-linked hydrogels of hyaluronic acid. Bioconjug Chem. 1997:8:686-694
42. Inukai M, Jin Y, Yomota C, Yonese M. Preparation and characterization of hyaluronate-hydroxyethyl acrylate blend hydrogel for controlled release device. Chem Pharm Bull. 2000; 48: 850-854
43. Leach JB, Schmidt CE. Characterization of protein release from photo-crosslinkable hyaluronic acid-polyethylene glycol hydrogel tissue engineering scaffolds. Biomaterials. 2005; 26: 125-135
44. Augst AD, Kong HJ, Mooney DJ. Alginate hydrogels as biomaterials. Macromol Biosci. 2006; 6: 623-633
45. Tønnesen HH, Karlsen J. Alginate in drug delivery systems. Drug Dcv md Pharm. 2002; 28: 621-630
46. Benson HA, Namjoshi S. Proteins and peptides: strategies for delivery to and across the skin. J Pharm Sci. 2008; 97: 3591-3610
47. Barbani N, Giusti P, Lazzeri L, Polacco G, Pizzirani G. Bioartificial materials based on collagen: 1. Collagen cross-linking with gaseous glutaraldehyde. J. Biomater Sci Polym Ed. 1995; 7: 461-469
48. Bradley WG, Wilkes GL. Some mechanical property considerations of reconstituted collagen for drug release supports. Biomater Med Devices Artif Organs. 1977; 5: 159-175
49. Ruderman RJ, Wade CWR, Shepard WD, Leonard F. Prolonged resorption of collagen sponges: vaporphase treatment with formaldehyde. J Biomater Res. 1973; 7: 263-265
50. Tu R, Lu CL, Thyagarajan K, Wang E, Nguyenm H, Shen 5, Hata C, Quijano RC. Kinetic study of collagen fixation with polyepoxy fixatives. J Biomed Mater Res. 1993; 27: 3-9.
51. Petite H, Rault I, Hue A, Menasche PH, Herbage D. Use of the acyl azide method for cross linking collagen rich tissues such as pericardium. J Biomed Mater Res. 1990; 24: 179-187
52. Nimni ME, Cheung D, Strates B, Kodama M, Sheikh K. Bioprosthesis derived from crosslinked and chemically modified collagenous tissue. In: Nimni ME, editor. Collagen biotechnology. Vol. 3. Boca Raton (FL): CRC Press; 1988. P. 1 38.
53. Chvapil M, Speer DP, Holubec H, Chvapil TA, King DR. Collagen fibers as a temporary scaffold for replacement of ACL in goats. J Biomed Mater Res. 1993; 27: 313-325
54. Harkness RD. Collagen. Sci Prog. 1966; 54: 257-274
55. Stenzel KH, Dunn MW, Rubin AL, Miyata T. Collagen gels: design for vitreous replacement. Science. 1969; 164: 1282-1283
56. Miyata T, Sohde T, Rubin AL, Stenzel RH. Effects of ultraviolet irradiation on native and telopeptide-poor collagen. Biochim Biophys Acta. 1971; 229: 672-680
57. Gorham SD, Light ND, Diamond AM, Willins MJ, Bailey AJ, Wess TJ, Leslie MJ. Effect of chemical modifications on the susceptibility of collagen to proteolysis. II. Dehydrothermal eros slinking. Tnt J Biol Macromol. 1992; 14: 129-138
58. Nicholas FL, Gagnieu CH. Denatured thiolated collagen. IL Crosslinking by oxidation. Biomaterials. 1977; 18: 815-821
59. Rao KP. Recent developments of collagen.based materials for medical applications and drug delivery systems. J Biomater Sci. 1995; 7: 623-645
60. Lucas PA, Syftestad GT, Goldberg VM, Caplan AT. Ectopic induction of cartilage and bone by water soluble proteins from bovine bone using a collagenous delivery vehicle. J Biomed Mater Res. 1989; 23: 23-39.
61. Miller JM, Zoll DR, Brown E0. Clinical observation on use of an extrude collagen suture. Arch Surg. 1964; 88: 167-174
62. Cameron WJ. A new topical hemostatic agent in gynecological surgery. Obstet Gynecol. 1978; 51: 118-122
63. Browder 1W, Litwin MS. Use of absorbable collagen for hemostasis in general surgical patients. Am Surg. 1986; 52: 492-494
64. Kemp PD. Tissue engineering and cell populated collagen matrices. Methods Mol Biol. 2000; 139: 287-293
65. Auger FA, Rouabhia M, Goulet F, Berthod F, Moulin V, Germain L. Tissue-engineered human skin substitutes developed from collagen populated hydrated gels: clinical and fundamental applications. Med Biol Eng Comput. 1998; 36: 801-812
66. Huynh T, Abraham G, Murray J, Brockbank K, Hagen PO, Sullivan S. Remodeling of a cellular collagen graft into a physiologically responsive neovessel. Nat Biotechnol. 1999; 17: 1083-1086
67. Kaufman HE, Steinemann TL, Lehman E, Thompson HW, Varnell ED, Jacob- La Barre JT, Gerhardt BM. Collagen based drug delivery and artificial tears. J Ocul Pharmacol. 1994; 10: 17-27.
68. Thacharodi D, Rao KP. Rate-controlling biopolymer membranes as transdermal delivery systems for nifedipine: development and in vitro evaluations. Biomaterials. 1996; 17: 1307-1311
69. Rossler B, Kreuter J, Scherer D. Collagen microparticles: preparation and properties. J Microencapsul. 1995; 12: 49-57.
70. Fonseca MJ, Alsina MA, Reig F. Coating liposomes with collagen (M 50000) increases uptake into liver. Biochim Biophys Acta. 1996; 1279: 259-265
71. Suzuki 5, Kawai K, Ashoori F, Morimoto N, Nishimura Y, Ikada Y. Long-term follow-up study of artificial dermis composed of outer silicone layer and inner collagen sponge. Br J Plast Surg. 2000; 53: 659-666
72. Friess W. Collagen-biomaterial for drug delivery. Eur J Pharm Biopharm. 1998; 45: 113-136
73. Doillon CJ, Silver FH. Collagen-based wound dressing effects of hyaluronic acid and fibronectin on wound healing. Biomaterials. 1986; 7: 3-8.
74. Lefebvre F, Gorecki 5, Bareilli R, Amedee J, Bordenave L, Rabaud M. New artificial connective matrix-like structure made of elastin solubilized peptides and collagens: elaboration, biochemical and structural properties. Biomaterials. 1992; 13: 28-33.
75. Lefebvre F, Pilet P, Bonzon N, Daculsi G, Rabaud M. New preparation and microstructure of the Endo-Patch elastin-collagen containing glycosaminoglycans. Biomaterials. 1996:17:1813-8.
76. Rubin AL, Stenzel KR, Miyata T, White MJ, Dunn M. Collagen as a vehicle for drug delivery. J Clin Pharm. 1973:13:309 12.
77. Bloomfield SE, Miyata T, Dunn MW, Bueser N, Stenzel KH, Rubin AL. Soluble gentamycin ophthalmic inserts as a drug delivery system. Arch Ophthalmol. 1978; 96: 885-887
78. Minabe M, Takeuchi K, Tamura K, Hon T, Umemoto T. Subgingival administration of tetracycline on a collagen film. J Periodontal Res. 1989; 60: 552-556
79. Minabe M, Uematsu A, Nishijima Momat K, Tomomatsu E, Tamura T, Hon T, Umemoto T, Hino T. Application of a local drug delivery system to periodontal therapy: I. Development of collagen preparations with immobilized tetracycline. J Periodontal Res. 1989; 60: 113-117
80. Sato H, Kitazawa H, Adachi I, Horikoshi I. Microdialysis assessment of microfibrous collagen containing ap-glycoprotein-mediated transport inhibitor, cyclosporine A, for local delivery of etopocide. Pharm Res. 1996; 13: 1565-1569
81. Murata M, Huang BZ, Shibata T, Imai 5, Nagai N. Arisue M. Bone augmentation by recombinant human BMP-2 and collagen on adult rat parietal bone. Tnt J Oral Maxillofac Surg. 1999; 28: 232-237
82. Murata M, Maki F, Sato D, Shibata T, Arisue M. Bone augmentation by only implant using recombinant human BMP-2 and collagen on adult rat skull without periosteum. Clin Oral Implants Res. 2000; 11: 289-295
83. Nakagawa T, Tagawa T. Ultrastructural study of direct bone formation induced by BMPs-collagen complex planted into an ectopic site. Oral Di 2000; 6: 172-179
84. Liu HW, Ofosu FA, Chang PL. Expression of human factor IX by microencapsulated recombinant fibroblasts. Hum Gene Ther. 1993; 4: 291-301.
85. Al-Hendy A, Hortelano G, Tannenbaum GS, Chan PL. Correction of the growth defect in dwarf mice with nonautologous microencapsulated myoblasts an alternative approach to somatic gene therapy. Hum Gene Ther. 1996; 6: 165-175
86. Tani K, Ozawa K, Ogura H, Takahashi T, Ohano A, Waters K, Matsudaira T, Tajika K, Karasuyama H, Nagata S. Asano S. Takeout F. Implantation of fibroblasts transfected with human granulocyte colony stimulating factor eDNA into mice as a model of cytokine supplements gene therapy. Blood. 1989; 74: 1274-1280
87. Brauker J, Carr-Brendel 5, Neunenfeldt 5, Clarke D, Hodgett D, Vergoth C, Stone W, Dwarki V, Chen R, Nijjar T. Loudovaris T, Martison L, Young 5, Jacobs 5, Geller R, Maryanov D, Levon 5, Johnston W, Johnson RC. Immunoisolation in somatic cell gene therapy. J Cell Biochem. 1995; 21B: 1-115.
88. Barr E, Leiden JM. Systemic delivery of recombinant proteins by genetically modified myoblasts. Science. 1991;254: 1507-1509
89. Scharfmann R, Axelord JH, Verma TM. Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc Natl Acad Sci U S A. 1991; 88: 4626-4630
90. Heartlein MW, Roman VA, Jiang JL, Sellers JW, Zuliani AIVI, Treco DA, Selden R. Long-term production and delivery of human growth hormone in vivo. Proc Nati Acad Sci U S A. 1994; 91: 10967-10971
91. Rosenthal FM, Kohler G. Collagen as matrix forneo-organ formation by genetransfected fibroblasts. Anticancer Res. 1997; 17: 1179-1186
92. Aebischer P, Schleup M, Deglon N, Joseph JM, Hirt L, Heyd B, Goddard M, Hammang, JP, Zurn AD, Kato AC, Regli F, Baetge FE. Intrathecal delivery of CNTF using encapsulated genetically modified xenogenic cells in amyotrophic lateral sclerosis. Nat Med. 1996; 2: 696-699
93. Park JC, Hwang YS, Lee JE, Park KD, Matsumura K, Hyon SH, Suh H. Type I atelocollagen grafting onto ozone-treated polyurethane films: cell attachment, proliferation, and collagen synthesis. J Biomed Mater Res. 2000; 52: 669-677
94. Moullier P, Bohl D, Heard JM, Danos 0. Correction of lysosomal storage in the liver and spleen of MPSVIT mice by implantation of genetically modified skin fibroblasts. Nature Genet. 1993; 4: 154-159
95. Moullier P, Marechal V, Danos 0, Heard JM. Continuous systemic secretion of lysosomal enzyme by genetically-modified mouse skin fibroblasts. Transplantation. 1993; 56: 427-432
96. Hellio D, Djabourov M. Physically and chemically crosslinked gelatin gels. Macromol Symp. 2006; 241: 23-27
97. Cutright DE, Perez E, Beasley JD, Larson WJ, Posey WR. Degradation rates of polymers and copolymers of polylactic and polyglycolic acids. Oral Surg Oral Med Oral Pathol. 1974; 37: 142-152
98. Jeffery H, Davis SS. O'Hagan DT. The preparation and characterization of poly (lactide-co-glycolide) microparticles IT: the entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique. Pharm Res. 1993; 10: 362-368
99. Porjazoska A, Goracinova K, Mladenovska K, Glavas M, Simonovska M. Janjevic El, Cvetkovska M. Poly (lactide-co-glycolide) microparticles as systems for controlled release of proteins-preparation and characterization. Acta Pharm. 2004; 54: 215-229
100. Berkland C, Kim K, Pack DW. PLG microsphere size controls drug release rate through several competing factors. Pharm Res. 2003; 20: 1055-1062
101. Berkland C, Kim K, Pack DW. Fabrication of PLG microspheres with precisely controlled and monodisperse size distributions. J Control Release. 2001; 73: 59-74.
102. Raman C, Berkland C, Kyekyoon KK, Pack DW. Modeling small molecule release from PLG microspheres: effects of polymer degradation and non-uniform drug distribution. J Control Release. 2005; 103: 149-158
103. Siepmann J, Faisant N, Akiki J, Richard J, Benoit JP. Effect of the size of biodegradable microparticles on drug release: experiment and theory. J Control Release. 2004; 96: 123-134
104. Bezemer JM, Radersma R, Grijpma DW, Dijkstra PJ, van Blitterswijk CA, Feijen J. Microspheres for protein delivery prepared from amphiphilic multiblock copolymers 2. Modulation of release rate. J Control Release. 2000; 67: 249-260
105. Berchane NS, Carson KH, Rice-Ficht AC, Andrews MJ. Effect of mean diameter and polydispersity of PLG microspheres on drug release: experiment and theory. Tnt J Pharm. 2007; 337: 118-126
106. Thong HY, Zhai H, Maibach HI. Percutaneous penetration enhancers: an overview. Skin Pharm Physiol. 2007; 20: 272-282
107. Aqil M, Ahad A, Sultana Y, Au A. Status of terpenes as skin penetration enhancers. Drug Discov Today. 2007; 12: 1061-1067
108. Sivakumar M, Tachibana K, Pandit AB, Yasui K, Tuziuti T, Towata A, lida Y. Transdermal drug delivery using ultrasound-theory, understanding and critical analysis. Cell Mol Biol (Noisy-le-grand). 2005; 2(51 suppl):0L767-84.
109. Lemarchand C, Gref R, Couvreur P. Polysaccharide-decorated nanoparticles. Eur J Pharm Biopharm. 2004; 58: 327-341
110. Fernandez-Urrusuno R, Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res. 1999; 16: 1576-1581
111. Listinsky JJ, Siegal GP, Listinsky CM. Alpha-L-fucose a potentially critical molecule in pathologic processes including neoplasia. Am J Clin Pathol. 1998; 110: 425-440
112. Home 5, Heinze T. Nanoscale structures of dextran esters. Carbohydr Polym. 2007; 68: 280-286
113. Alvarez-Roman R, Naik A, Kalia Y, Guy RH, Fessi H. Skin penetration and distribution of polymeric nanoparticles. J Control Rd. 2004; 99: 53-62.
114. Potts RO, Cleary GW. Transdermal drug delivery: useful paradigms. J Drug Target. 1995; 3: 247-251
115. Alvarez R, Elbashir 5, Borland T, Toudjarska I, Hadwiger P, John M, Roehl I, Morskaya SS, Martinello R, Kahn J, Van Ranst M, Tripp RA, DeVincenzo JP, Pandey R, Maier M, Nechev L, Manoharan M, Kotelianski V, Meyers R. RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother. 2009; 53: 3952-3962
116. Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharmacol. 2009; 6: 659-668
117. Gonzalez-Gonzalez E, Ra H, Hickerson RP, Wang Q, Piyawattanametha W, Mandella MJ, Kino GS. Leake D, Avilion AA. Solgaard 0, Doyle TC, Contag CH, Kaspar RL. siRNA silencing of keratinocyte-specific GFP expression in a transgenic mouse skin model. Gene Ther. 2009; 16: 963-972
118. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature. 2004; 431: 371-378
119. Takeshita F, MinakuchiY, Nagahara 5, Honma K, Sasaki H, Hirai K, Teratani T, Namatame N, Yamamoto Y, Hanai K, Kato T, Sano A, Ochiya T. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci U S A. 2005; 102: 12177-12182
120. Palliser D, Chowdhury D, Wang QY. Lee SJ, Bronson RT, Knipe DM, Lieberman J. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature. 2006; 439: 89-94.
121. Kigasawa K, Kajimoto K, Hama 5, Saito A, Kanamura K. Kogure K. Noninvasive delivery of siRNA into the epidermis by iontophoresis using an atopic dermatitis-like model rat. Tnt J Pharm. 2010; 383: 157-160
122. Wang Q, Ilves H, Chu P, Contag CH, Leake D, Johnston BH, Kaspar RL. Delivery and inhibition of reporter genes by small interfering RNAs in a mouse skin model. J Invest Dermatol. 2007; 127: 2577-2584
123. Nakamura M, Jo J, Tabata Y, Ishikawa 0. Controlled delivery of T-box2 1 small interfering RNA ameliorates autoimmune alopecia (Alopecia Areata) in a C3H/ HeJ mouse model. Am J Pathol. 2008; 172: 650-658